A Unique Time for Investors

The trend of increased healthcare spending and technology advancements, and the unmet medical needs for cures and treatments will continue to provide the biotech sector with growth and advancements, as well as lucrative investment opportunities.

According to the drugmaker GlaxoSmithKline, the total market for cancer drugs is expected to nearly double to $70 billion by 2009.

Our goal is to search for small biotech companies that may be tomorrow's industry leaders and to discover the gems of medical biotech. We seek out those biotech companies that may one day deliver groundbreaking drugs for Alzheimer’s disease, cancer, multiple sclerosis, etc. In the biotech sector these great investment opportunities present themselves more frequently than one might expect, however; knowing which science to invest in is a huge challenge that requires specialized skills, education, and years of training.

While there may be plenty of promising small to mid-caps biotech’s with exciting science/drugs and solid management teams, for many individual investors the complexity of the science and the regulatory processes can be daunting. InvestBio has the scientific, medical, and financial intelligence required to analyze and discover the most promising biotech investments.

When most biotechnology companies are in the development-stage, they may be difficult to value, as often they have little to no income. What analysts can evaluate, once clinical trials are carried out, is the state of knowledge about a given indication, the validity of the drug target, and the maturity of the underlying technology. Once a biotech company begins to make money, it can then be valued like most companies.

InvestBio believes that most investment banks on Wall Street do not closely follow the small and mid-cap biotech sector, and that many analysts are not adequately qualified to fairly evaluate many of the biotech companies. There are about forty Wall Street analysts who follow this sector (and often only the companies that their firm has brought public, plus some of the large cap biotech’s). This lack of coverage, especially for small and mid-cap biotech’s, provides buying opportunities for the knowledgeable investor.

InvestBio brings together all the elements required to make knowledgeable and successful investments by utilizing our Executive and Advisory Network. This team consists of practicing physicians, biotech researchers and scientists, successful biotech entrepreneurs, and experienced biotech investors.

Before investing in biotechnology it is also important to be aware of the potential risks. These risks can be reduced by constructing a portfolio of promising biotech companies representing different types of experimental drugs at different stages of development. See our Do’s and Don’ts of Biotech Investing and our Suitability and Risks section.

For biotech investing questions please contact *DPEC Partners.

* InvestBio does not offer any securities. InvestBio’s biotech investment products and services can only be obtained through DPEC Capital, Inc.